Why Novo Nordisk Stock Slipped Today

Novo Nordisk (NVO) shares declined nearly 4% after its Q2 2025 results missed analyst expectations, reporting $11.9 billion in revenue and $0.92 EPS, despite year-over-year growth. This "double miss" and the stock's underperformance are driven by intensifying competition from licensed drugs like Eli Lilly's Zepbound and the proliferation of copycat compounded products, prompting 146 lawsuits. The company had also significantly cut its full-year guidance in late July, signaling mounting pressure on its key obesity and diabetes franchises.

Analysis

Novo Nordisk's second-quarter 2025 results reveal mounting pressure on its core obesity and diabetes franchises, leading to a stock decline of nearly 4% against a positive S&P 500. The company reported a "double miss" with revenue of $11.9 billion and EPS of $0.92, falling short of consensus estimates of just under $12 billion and $0.95, respectively. While year-over-year growth remains strong, with revenue up 13% and net income up 32%, the marginal sequential revenue increase signals a potential deceleration. This slowdown is directly attributed to intensifying competition from Eli Lilly's Zepbound and the proliferation of compounded copycats of its key drug, Wegovy. The severity of this threat is underscored by the 146 lawsuits Novo Nordisk has filed across 40 states. Importantly, this earnings miss compounds negative sentiment following a significant cut to full-year sales and operating profit guidance issued in late July, indicating that competitive headwinds are materially impacting the company's financial outlook.

Key Decisions for Investors

• Given the earnings miss and prior guidance cut, investors should closely monitor sales data for further evidence of market share erosion to competitors, particularly Eli Lilly.
• The 146 lawsuits against compounded products represent a significant operational and legal risk; the outcomes of this litigation could materially impact revenue and should be tracked as a key performance indicator.
• Consider the relative strength of competitor Eli Lilly, which is cited as gaining traction, as a potential hedge or alternative allocation within the anti-obesity drug market.
• The marginal sequential revenue growth, despite strong year-over-year figures, warrants caution and a re-evaluation of growth sustainability in the face of heightened competition.